1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Nang Kuang Pharmaceutical Co., Ltd.

Nang Kuang Pharmaceutical Co., Ltd.

TTWSE:1752
31.10
TWD
-0.15
(-0.48%)
2.01EPS
16.51P/E
3.38BMarket Cap
Nov 06Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
11.85
14.33
16.6
15.44
14.89
15.24
17.59
17.38
17.63
19.21
21.29
21.78
21.41
20.84
Basic EPS, GAAP
-0.09
0.76
2.17
2.25
1.84
1
2.17
1.82
1.94
3.49
1.96
2.41
2.42
2.03
Free Cash Flow per Basic Share
-1.23
1.35
0.54
1.75
1.17
2.07
3.11
0.59
3.93
2.72
0.41
-0.59
1.81
1.38
Dividend per Share
0.26
0.28
0.49
1.2
1.6
1.6
0.9
1.2
1.5
1.55
2
1
0.8
- -
Book Value per Share
15.99
16.17
20.97
21.02
21.22
20.52
21.66
21.83
22.18
23.87
23.54
23.98
24.6
23.84
Tangible Book Value per Share
15.96
16.09
20.87
20.91
21.14
20.45
21.62
21.8
22.13
23.84
23.49
23.94
24.55
23.75
Basic Weighted Avg Shares
85
89
92
100
101
101
100
101
101
101
101
101
101
101
Sales/Revenue/Turnover
1,013
1,277
1,520
1,550
1,504
1,539
1,762
1,755
1,780
1,940
2,150
2,200
2,162
2,109
Operating Margin (%)
-0.04
7.18
13.88
14.83
10.71
8.3
14.07
12.83
14.41
16.69
15.75
13.98
13.67
12.39
Depreciation Expense
121
153
164
172
178
196
193
185
180
176
182
183
183
181
Net Income, GAAP
-8
67
199
225
186
101
217
183
196
352
198
243
244
205
Effective Tax Rate (%)
237.11
18.54
12.2
16.55
14.63
14.02
13.31
17.98
16.46
14.28
7.15
19.72
16.21
16.13
Profit Margin (%)
-0.77
5.27
13.09
14.55
12.36
6.58
12.34
10.45
11.02
18.14
9.23
11.06
11.3
9.74
Working Capital
495
482
452
331
248
183
398
485
418
600
255
313
428
463
LT Debt
851
790
356
208
156
104
53
50
39
26
13
168
186
305
Total Equity
1,426
1,441
1,994
2,123
2,143
2,053
2,187
2,205
2,240
2,411
2,377
2,422
2,490
2,412
Return on Invested Capital (%)
0.03
3.03
7.01
6.75
4.69
3.98
8.25
6.83
7.89
9.68
8.23
8.22
7.94
7.12
Return on Capital (%)
-0.93
3.01
7.89
8.18
6.51
3.85
8.57
7.05
7.29
12.73
7.07
8.2
8.12
7.05
Return on Common Equity (%)
-0.67
4.69
11.58
10.95
8.71
4.82
10.26
8.35
8.82
15.14
8.29
10.14
9.96
8.57

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
470
509
379
LT Borrowings
186
184
302
LT Finance Leases
- -
- -
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
101
101
101
Market Capitalization
3,767
3,615
3,383

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,493
1,514
1,605
Cash, Cash Equivalents & STI
351
331
385
Accounts Receivable, Net
253
265
273
Inventories
663
666
704
Total Current Liabilities
1,065
1,242
1,141
Payables & Accruals
- -
- -
- -
ST Debt
470
509
379
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.31%
2.51%
2.8%
Free Cash Flow
7.1%
-39.24%
-407.68%
Net Income, GAAP
11.52%
13.18%
0.41%
Sales/Revenue/Turnover
3.73%
4.37%
-1.71%
Total Cash Common Dividend
- -
-2.53%
-20%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
528
512
580
579
2,200
2025
579
542
524
517
2,162
2026
530
539
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.54
0.44
0.58
0.86
2.41
2025
0.71
0.51
0.46
0.73
2.42
2026
0.32
0.52
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
0.8
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yue Pei Wang
Full Time Employees
552
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 1001, Zhongshan Road Tainan TQ Taiwan 71243
IPO Date
Aug 10, 2009
Website
nangkuang.com.tw
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Nang Kuang Pharmaceutical Co., Ltd. manufactures, processes, trades, imports, and exports pharmaceuticals and medical devices principally in Taiwan, China, Japan, the United States, and other international markets. Founded in 1963 and headquartered in Xinhua District, Tainan City, Taiwan, the company specializes in sterile injectables including ready-to-use injections, prefilled syringes, premixed IV infusions, powder injections, and non-PVC IV infusion bags; solid formulations such as hard capsules, tablets, film-coated tablets, granules, and creams; and therapeutic products covering cardiovascular, gastrointestinal, nervous system, musculo-skeletal, respiratory, alimentary and metabolism, blood and hematological agents, antineoplastic and immunomodulatory drugs, dermatologicals, genito-urinary and sex hormones, systemic hormones, antibacterials, cosmetics, eye drops, anti-aging and preventive medicines, chemotherapy and oncology products, as well as hospital solutions. It operates manufacturing facilities certified under PIC/S GMP by Taiwan's health authority and Japan's PMDA, with ISO 14001 and TIPS certifications, and holds export approvals to multiple countries. In recent developments, Nang Kuang launched new sleep-aid treatment Ramesson and benign prostatic hyperplasia treatment Finta to boost market share in quality-of-life medications, projecting continued revenue growth into 2025; the company maintains strategic focus on acute and critical care, anti-aging and preventive medicine development, and international alliances in Asia-Pacific, Europe, and the Americas, while enhancing corporate governance through ESG initiatives and talent strategies as highlighted at the 2025 KPMG Leadership Academy Forum.